Autofagia
Os inibidores da autofagia têm como alvo o processo celular de autofagia, que envolve a degradação e reciclagem de componentes celulares através dos lisossomas. A autofagia é um mecanismo crítico para a manutenção da homeostase celular, mas sua desregulação está implicada em várias doenças, incluindo câncer, neurodegeneração e infecções. Os inibidores da autofagia podem bloquear este processo, tornando-os ferramentas valiosas para estudar o papel da autofagia nas doenças e desenvolver estratégias terapêuticas. Na CymitQuimica, oferecemos inibidores da autofagia para apoiar sua pesquisa em biologia celular, oncologia e doenças neurodegenerativas.
Foram encontrados 1489 produtos de "Autofagia"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
p38 MAPK-IN-1
CAS:p38 MAPK-IN-1 is a novel selective p38 MAPK inhibitor with high potency, which reduces inflammatory responses by inhibiting LPS-induced TNF-α production.Fórmula:C21H14F2N2OPureza:98%Cor e Forma:SolidPeso molecular:348.35TIQ-15
CAS:TIQ-15 is an effective and selective CXCR4 antagonist. It has good drug-like properties.Fórmula:C23H32N4Pureza:98%Cor e Forma:SolidPeso molecular:364.53CXCR2-IN-2
CAS:CXCR2-IN-2: A selective, brain-penetrant, oral CXCR2 inhibitor (IC50: 5.2 nM/1 nM). ~730x selectivity vs CXCR1, >1900x vs other chemokine receptors.Fórmula:C18H23ClN2O5SCor e Forma:SolidPeso molecular:414.9Antitumor agent-82
Antitumor agent-82: potent, anti-proliferative, induces autophagy via ATG5/ATG7.Fórmula:C32H42N6Cor e Forma:SolidPeso molecular:510.72Ruxolitinib sulfate
CAS:Ruxolitinib sulfate, a potent JAK1/2 inhibitor (IC50: 3.3/2.8 nM), is >130x more selective for JAK1/2 than JAK3.Fórmula:C17H20N6O4SCor e Forma:SolidPeso molecular:404.45AZD0233
CAS:AZD0233 is an orally-active CX3CR1 antagonist. AZD0233 can regulate the CX3CR1/CX3CL1 signaling axis, and has excellent physicochemical properties, metabolic stability, low toxicity and CYP inhibitory characteristics.Fórmula:C19H29FN6O4SPeso molecular:456.54LY2955303
CAS:LY2955303 is an effective and selective antagonist of retinoic acid receptor gamma (RARγ, Ki = 1.09 nM).Fórmula:C36H42N4O3Pureza:98.56% - 99.85%Cor e Forma:SolidPeso molecular:578.74RK-682
CAS:RK-682 is a natural selective inhibitor of protein tyrosine phosphatases (PTPases).Fórmula:C21H36O5Cor e Forma:SolidPeso molecular:368.51AGN-195183
CAS:AGN 195183: RARα agonist, Kd=3 nM, selective, no RARβ/γ effect, inhibits breast cancer cells, in Phase I/II clinical trials, non-irritant.Fórmula:C22H22ClF2NO4Cor e Forma:SolidPeso molecular:437.86Di-N-desethyl amiodarone hydrochloride
CAS:Di-N-desethyl Amiodarone hydrochloride, a metabolite of Amiodarone, functions as a potent inhibitor of the respiratory chain [1].Fórmula:C21H22ClI2NO3Pureza:98%Cor e Forma:SolidPeso molecular:625.676CEPN
CAS:6CEPN is a Cyclooxygenase-1 inhibitor that acts by suppressing colorectal cancer growth.Fórmula:C23H18O5Cor e Forma:SolidPeso molecular:374.39Ladarixin Sodium
CAS:Ladarixin Sodium, an Chemokine CXCR antagonist, is used potentially for the treatment of type I diabetes.Fórmula:C11H12F3NNaO6S2Cor e Forma:SolidPeso molecular:398.32PHY34
CAS:PHY34 inhibits autophagy at nanomolar potency, with anti-tumor effects on HGSOC in vivo.Fórmula:C30H30O12Pureza:98.71%Cor e Forma:SolidPeso molecular:582.55Ref: TM-T37376
1mg164,00€2mg235,00€5mg369,00€10mg548,00€25mg879,00€50mg1.198,00€100mg1.596,00€500mg3.212,00€CXCR2-IN-1
CAS:CXCR2-IN-1 has a pIC50 of 9.3 and is a CXCR2 antagonist of the central nervous system penetration agent.Fórmula:C19H20Cl2FN3O4SPureza:99.89%Cor e Forma:SolidPeso molecular:476.35SAFit2
CAS:<p>SAFit2 is a highly potent and selective inhibitor of fk506 binding protein 51 (FKBP51).Cost-effective and quality-assured</p>Fórmula:C46H62N2O10Pureza:98.16% - >99.99%Cor e Forma:SolidPeso molecular:802.99AZ PFKFB3 26
CAS:<p>AZ PFKFB3 26 is an effective and selective PFKFB3 inhibitor with an IC50 of 23 nM. The IC50s for PFKFB1 and PFKFB2 are 2.06 and 0.384 μM, respectively.</p>Fórmula:C24H26N4O2Pureza:99.85%Cor e Forma:SolidPeso molecular:402.49GDC-0349
CAS:<p>GDC-0349 (RG-7603) is a potent and selective ATP-competitive inhibitor of mTOR, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.</p>Fórmula:C24H32N6O3Pureza:96.00% - 98.17%Cor e Forma:SolidPeso molecular:452.55CCX662
CAS:CCX662 is a CXCR7 antagonist. It inhibits the binding of 125I-CXCL12 to CXCR7 with an IC50 of 9 nM. This compound is suitable for use in cancer research.Fórmula:C28H37N5O4SCor e Forma:SolidPeso molecular:539.69SHS206
SHS206 (compound 6n) is an orally active mitochondrial uncoupler that decreases triglyceride levels in the liver. Demonstrating in vivo efficacy in a GAN mouse model, SHS206 also exhibits inhibitory effects on metabolic dysfunction-associated steatohepatitis (MASH).Fórmula:C14H7F6N3OCor e Forma:SolidPeso molecular:347.22ACT-777991
CAS:ACT-777991: oral CXCR3 blocker, stable in microsomes/hepatocytes, inhibits T-cell migration to CXCL11.Fórmula:C20H20F6N8O2SCor e Forma:SolidPeso molecular:550.48(R)-SCH 546738
CAS:(R)-SCH 546738, the R-isomer of SCH 546738, is a non-competitive, orally active antagonist targeting the CXCR3 receptor, exhibiting a K_i of 0.4 nM for the human CXCR3 receptor.Fórmula:C23H31Cl2N7OCor e Forma:SolidPeso molecular:492.45PARL-IN-1
PARL-IN-1: Strong PARL blocker, IC50 28 nM, boosts PINK1/Parkin mitophagy.Fórmula:C40H58N6O7Cor e Forma:SolidPeso molecular:734.92LRRK2-IN-12
CAS:LRRK2-IN-12 (compound 1) is a potent inhibitor of LRRK2 (G20195) with an IC 50 of 0.45 nM, LRRK2 WT with an IC 50 of 1.1 nM, and LRRK2 WT ADP-Glo with an IC 50 of 0.46 nM. This compound is utilized in research related to Alzheimer's Disease [1].Fórmula:C18H17ClN8O2Cor e Forma:SolidPeso molecular:412.83SORT1-IN-2
CAS:SORT1-IN-2 (compound 6) is an inhibitor of SORT1.Fórmula:C21H29N3O4Cor e Forma:SolidPeso molecular:387.47ATG12-IN-1
CAS:ATG12-IN-1 (compound 4) acts as an autophagy inhibitor targeting the ATG12-ATG3 protein-protein interaction (IC50= 9 μM), suitable for research in cancer studies.Fórmula:C23H15ClN4O2Cor e Forma:SolidPeso molecular:414.84ACT-672125
CAS:ACT-672125: Potent CXCR3 blocker, may treat autoimmunity, safe with dose-dependent efficacy in lung inflammation.Fórmula:C25H25F3N10O2SCor e Forma:SolidPeso molecular:586.59SYUIQ-5
CAS:SYUIQ-5 is a ligand for G-quadruplex structures. It plays a role in stabilizing G-quadruplexes and inducing senescence. Additionally, SYUIQ-5 inhibits the activity of the c-myc gene promoter. By displacing TRF2 from telomeres, SYUIQ-5 induces telomeric damage, which triggers autophagy (autophagy) in cancer cells.Fórmula:C20H22N4Cor e Forma:SolidPeso molecular:318.415LC3B recruiter 1
CAS:LC3B recruiter 1 (compound 33R) is an LC3B recruiting fragment. It directly interacts with LC3B, exhibiting a Kd value of 2.87 µM.Fórmula:C14H10ClN3O2Cor e Forma:SolidPeso molecular:287.701Autophagy activator-1
CAS:<p>Autophagyactivator-1 (Compound B2) is an autophagy activator that induces autophagy by downregulating key members of the HSP70 family and activating the unfolded protein response.</p>Fórmula:C25H32O8Cor e Forma:SolidPeso molecular:460.517HMG499
CAS:HMG499 inhibits HMG-CoA reductase (IC50: 0.41μM), reduces statin-induced HMGCR, lowers cholesterol, and lessens atherosclerosis.Fórmula:C33H54O3Pureza:98%Cor e Forma:SolidPeso molecular:498.78(R,R)-LRRK2-IN-7
CAS:(R,R)-LRRK2-IN-7 is an isomer of LRRK2-IN-7, a potent and selective LRRK2 kinase inhibitor with CNS penetrance. It exhibits an IC50 of 0.9 nM and demonstrates over 1000-fold selectivity compared to other kinases, ion channels, and CYP enzymes.Fórmula:C24H26N6OPeso molecular:414.50SCH-900875
CAS:SCH-900875 is an orally active, brain-penetrant, and selective inhibitor of the CXCR3 receptor, demonstrating significant selectivity towards CXCR1 and CXCR2 receptors as well. By binding to CXCR3, SCH-900875 blocks the ligands CXCL9, CXCL10, and CXCL11, thereby inhibiting downstream G protein and β-arrestin signaling pathways and reducing inflammation cell migration. This compound holds potential for research into autoimmune diseases (such as rheumatoid arthritis and multiple sclerosis) and inflammatory conditions (such as psoriasis and inflammatory bowel disease).Fórmula:C28H37ClN8O2Cor e Forma:SolidPeso molecular:553.10CXCR4 antagonist 10
CAS:CXCR4 antagonist10 (compound 21) is an effective CXCR4 inhibitor with an IC50 value of 7.8 nM. It plays a significant role in cancer research.Fórmula:C18H18N4O4Cor e Forma:SolidPeso molecular:354.36CXCR7 antagonist-1 hydrochloride
CAS:CXCR7 antagonist-1 hydrochloride blocks SDF-1 and I-TAC from CXCR7; may prevent cancer and inflammation.Fórmula:C21H20ClFN6OCor e Forma:SolidPeso molecular:426.87YOK-1304
CAS:YOK-1304, an autophagy-targeting chimera (AUTOTAC), induces self-oligomerization of p62.Fórmula:C28H35NO4Cor e Forma:SolidPeso molecular:449.58SLW131
CAS:SLW131 (Compound 10) is a CCR7 antagonist with strong affinity, showing a Ki of 9.85 nM. It inhibits CCL19-induced Go protein activation with an IC50 of 29.4 μM and β-arrestin2 recruitment with an IC50 of 6.0 μM. SLW131 also suppresses CCL19-induced morphological changes in primary BMDC cells and CCR7-mediated migration of mouse CD4+ T cells.Fórmula:C21H27N5O5SCor e Forma:SolidPeso molecular:461.535LRRK2-IN-16
CAS:LRRK2-IN-16 (compound 25) is an inhibitor of the LRRK2 kinase with an IC50 value of less than 5 μM. It is applicable for research in neurodegenerative and autoimmune diseases.Fórmula:C18H19N5OSCor e Forma:SolidPeso molecular:353.441LRRK2-IN-14
CAS:LRRK2-IN-14 (Compound 8), an orally active inhibitor of LRRK2, exhibits an IC 50 of 6.3 nM against LRRK2(G2019S) cell activity and demonstrates inhibitory effects on hERG with an IC 50 of 22 μM. Additionally, LRRK2-IN-14 is permeable to the blood-brain barrier [1].Fórmula:C17H18F3N5O2Cor e Forma:SolidPeso molecular:381.35CXCR2 antagonist 7
CXCR2 antagonist 7 is a powerful blocker with IC50s: 0.044 μM for binding, 0.66 μM for calcium mobilization.Fórmula:C14H14F2N6OSCor e Forma:SolidPeso molecular:352.36HDAC10-IN-1
HDAC10-IN-1 is a potent, selective HDAC10 inhibitor (IC50=58 nM) affecting autophagy in FLT3-ITD+ acute myeloid leukemia cells.Fórmula:C18H23N3O2Cor e Forma:SolidPeso molecular:313.39CXCR4 antagonist 3
CXCR4 antagonist 3, aka compound 12a, has 11 nM IC50, shares TIQ15 traits, and is promising in HIV research.Fórmula:C22H31N5Cor e Forma:SolidPeso molecular:365.52Autophagy-IN-7
CAS:<p>Autophagy-IN-7 is an autophagy inhibitor for use in studying solid tumours.</p>Fórmula:C15H11N7Pureza:98.47%Cor e Forma:SolidPeso molecular:289.29Autophagy-lysosome activator-1
Autophagy-lysosome Activator-1 (Compound F1) is an autophagy-lysosome stimulator that effectively induces the degradation of PD-L1 or VISTA in tumor cells.Fórmula:C17H18N4O2Cor e Forma:SolidPeso molecular:310.35EMU-116
CAS:EMU-116 is an orally active antagonist of CXCR4, utilized in cancer research.Fórmula:C25H35N5Cor e Forma:SolidPeso molecular:405.58QW24
CAS:QW24 down-regulates BMI-1, exhibits potent antitumour effects and is used as an effective therapeutic agent in the treatment of clinical colorectal cancer.Fórmula:C27H28N2O4Cor e Forma:SolidPeso molecular:444.524-FPBUA
CAS:4-FPBUA, a semi-synthetic analog of lichen acid, enhances the functionality of cell-based blood-brain barriers (BBB) and increases the transport of β-amyloid (Aβ) in monolayer cells. Additionally, it acts as an inhibitor of mTOR, enhancing cellular autophagy (Autophagy) which can reverse BBB disruption in vivo, making it relevant for research in Alzheimer's disease.Fórmula:C31H23FO7Cor e Forma:SolidPeso molecular:526.51CXCR2/CCR7 antagonist-1
CAS:CXCR2/CCR7 antagonist-1 (compound 6) is a potent dual antagonist of CXCR2 and CCR7, with IC50 values of 0.0046 μM and 0.0014 μM, respectively. It is valuable for research in tumor metastasis and autoimmune diseases.Fórmula:C23H27N3O5Cor e Forma:SolidPeso molecular:425.48LRRK2-IN-2
CAS:LRRK2-IN-2: selective, potent LRRK2 inhibitor, IC50 of 0.6 nM, oral, crosses blood-brain barrier, for Parkinson's research.Fórmula:C23H23Cl2F3N6O2Cor e Forma:SolidPeso molecular:543.37LRRK2-IN-13
CAS:LRRK2-IN-13 (Compound 13), with an IC50 value of 0.57 nM, serves as an inhibitor of LRRK2 and exhibits properties that allow it to penetrate the brain [1].Fórmula:C19H19ClN8O2Cor e Forma:SolidPeso molecular:426.86ST-539
CAS:ST-539 is an inhibitor of the deubiquitinating enzyme USP30, with an IC50 of 0.37 μM. It enhances the ubiquitination of mitochondrial proteins and induces mitophagy (autophagy), thereby regulating mitochondrial homeostasis. ST-539 is applicable for research in neurodegenerative diseases.Fórmula:C30H31N3O4SCor e Forma:SolidPeso molecular:529.65CXCR2 antagonist 4
CXCR2 antagonist 4 inhibits CXCR2 (IC50: 0.13 μM) and CXCL8-induced calcium rise (IC50: 27 μM), promising for cancer research.Fórmula:C15H14F2N4OS2Cor e Forma:SolidPeso molecular:368.42DQ661
CAS:DQ661 is a potent inhibitor of PPT1 and a dimeric quinacrine autophagy (autophagy) inhibitor. It effectively suppresses the activity of mTORC1 and reduces protein expression levels of pS6K T389 and pS6 S240-244. Additionally, DQ661 exhibits anticancer properties.Fórmula:C41H47Cl2N5O2Cor e Forma:SolidPeso molecular:712.75SRI-31255
CAS:SRI-31255 is an orally active LRRK2 inhibitor, with IC50 values of 520 nM for human wild-type (WT) and 427 nM for the G2019S mutant. It inhibits kinase activity by binding to the ATP-binding pocket of LRRK2, providing neuroprotective effects. SRI-31255 serves as a lead compound for developing LRRK2-targeted therapies for Parkinson’s disease research.Fórmula:C15H14N4Cor e Forma:SolidPeso molecular:250.30LRRK2-IN-6
LRRK2-IN-6 is an oral, selective LRRK2 inhibitor crossing the blood-brain barrier, targeting GS (IC50: 4.6μM) and WT LRRK2 (IC50: 49μM).Fórmula:C23H24F2N4O2SCor e Forma:SolidPeso molecular:458.52Anle138b-F105
CAS:<p>Anle138b-F105 is an autophagy-targeting chimera (AUTOTAC) with a DC50 value of 3 nM. It targets tauP301L for lysosomal degradation.</p>Fórmula:C36H37FN4O5Cor e Forma:SolidPeso molecular:624.7SH498
CAS:<p>SH498 is a novel Bmi-1-mediated anti-tumor agent with significant anti-proliferative effects.</p>Fórmula:C27H25F3N2O4Cor e Forma:SolidPeso molecular:498.49LRRK2-IN-3
CAS:LRRK2-IN-3: potent, selective oral LRRK2 blocker, BBB-penetrant, IC50 of 0.6 nM in hPBMCs, for Parkinson's research.Fórmula:C25H29ClF2N6O2Cor e Forma:SolidPeso molecular:518.99Hesperadin hydrochloride
Hesperadin hydrochloride is an ATP-competitive indolone inhibitor of Aurora A and B, with an IC50 value of 250 nM for Aurora B.Fórmula:C29H33ClN4O3SCor e Forma:SolidPeso molecular:553.12LRRK2-IN-4
CAS:LRRK2-IN-4: Potent, selective LRRK2 inhibitor, oral, BBB-penetrating, IC50=2.6 nM, potential for Parkinson's.Fórmula:C25H29ClF2N6O2Cor e Forma:SolidPeso molecular:518.99YW3-56 (hydrochloride) (technical grade)
CAS:YW3-56: PAD2 & PAD4 inhibitor (IC50 = 0.5-5 μM), halts U2OS cell growth (IC50 ~2.5 μM), reduces S-180 & MDA-MB-231 tumor growth in mice.Fórmula:C27H33Cl2N5O2Cor e Forma:SolidPeso molecular:530.49BRD5631
CAS:BRD5631 is an autophagy enhancer, enhances autophagy through an mTOR-independent pathway.Fórmula:C30H35N3O4Pureza:98%Cor e Forma:SolidPeso molecular:501.62LRRK2-IN-19
CAS:LRRK2-IN-19 is a PROTAC-targeted protein ligand utilized in the synthesis of PROTAC JH-XII-03-02. JH-XII-03-02 acts as an effective and selective LRRK2 PROTAC degrader, which is applicable for research in Parkinson's disease.Fórmula:C19H22N6OCor e Forma:SolidPeso molecular:350.42LRRK2-IN-5
LRRK2-IN-5 is an oral, BBB-penetrating selective inhibitor for LRRK2 with IC50s: 1.2μM (GS) and 16μM (WT); halts LRRK2 autophosphorylation.Fórmula:C24H26F2N4O2SCor e Forma:SolidPeso molecular:472.55LRRK2-IN-20
CAS:LRRK2-IN-20 (EX. 4.64) is a selective inhibitor of LRRK2 with a potency of pIC50 at 0.7921 nM. This compound is applicable in research studies focused on Parkinson's Disease (PD).Fórmula:C24H32ClN7OCor e Forma:SolidPeso molecular:470.01CXCR2 antagonist 5
<p>CXCR2 antagonist 5 (compound 25) binds strongly (IC50=0.013μM) and mobilizes calcium (IC50=0.1μM).</p>Fórmula:C15H14F2N4O2SCor e Forma:SolidPeso molecular:352.36DC-LC3in-D5
CAS:DC-LC3in-D5 is a potent and selective covalent inhibitor of LC3A/B that disrupts autophagy by covalently binding to Lys49 on LC3B.Fórmula:C19H22Cl2N2O3Pureza:99.79%Cor e Forma:SolidPeso molecular:397.3Ref: TM-T61871
1mg99,00€5mg235,00€10mg376,00€25mg753,00€50mg1.169,00€100mg1.833,00€200mg2.460,00€1mL*10mM (DMSO)259,00€Rosiglitazone sodium
CAS:Rosiglitazone sodium is an effective and selective PPARγ activator, with EC50 values of 30 nM for PPARγ1, 100 nM for PPARγ2, and 60 nM for PPARγ. It also has an approximate Kd of 40 nM for PPARγ. Additionally, Rosiglitazone sodium acts as a regulator of TRP channels, inhibiting the activities of TRPM2 and TRPM3, while activating TRPC5.Fórmula:C18H18N3NaO3SCor e Forma:SolidPeso molecular:379.41HDAC1-IN-8
CAS:HDAC1-IN-8 (compound 5c) is a potent and selective HDAC1 inhibitor, with IC50 values of 11.94 µM for HDAC1, 22.95 µM for HDAC6, and greater than 500 µM for HDAC8. It exhibits antiproliferative activity, induces cell cycle arrest in G1 and G2/M phases, and triggers autophagy (autophagy). Additionally, HDAC1-IN-8 demonstrates anticancer properties and holds potential for lung cancer research.Fórmula:C22H24N2O4Cor e Forma:SolidPeso molecular:380.437BRD1991
CAS:BRD1991 is a chemical compound that specifically disrupts the interaction between Beclin 1 and Bcl-2, thereby inducing autophagy.Fórmula:C33H35Cl2N3O4Cor e Forma:SolidPeso molecular:608.55Acetylpepstatin
CAS:Acetylpepstatin is an inhibitor of HIV-1 protease, HIV-2 protease, aspartyl protease.Fórmula:C33H61N5O11Pureza:98%Cor e Forma:SolidPeso molecular:703.875Stauprimide
CAS:Stauprimide inhibits MYC by blocking NME2, reducing MYC transcription in ESCs.Fórmula:C35H28N4O5Pureza:98%Cor e Forma:SolidPeso molecular:584.62HDAC10-IN-2
HDAC10-IN-2, a selective HDAC10 inhibitor (IC50=20nM), modulates autophagy in FLT3-ITD+ acute myeloid leukemia.Fórmula:C19H22N2O2Cor e Forma:SolidPeso molecular:310.39CXCR2 antagonist 6
CXCR2 antagonist 6: strong CXCR2 affinity (IC50=0.044 μM), hinders calcium mobilization (IC50=0.66 μM).Fórmula:C17H16F2N4OSCor e Forma:SolidPeso molecular:362.4CXCR4 modulator-1
CAS:CXCR4 modulator-1 (ZINC72372983) is potent (EC50=100nM) with uses in anti-inflammatory, anticancer, and anti-HIV research.Fórmula:C23H27N5O2Cor e Forma:SolidPeso molecular:405.49SW063058
CAS:SW063058 is an autophagy inducer that specifically disrupts the interaction between Beclin 1 and Bcl-2 without affecting the interactions of Bcl-2 with pro-apoptotic members (such as Bax and BIM). By inhibiting the negative regulation of Beclin 1 (key to autophagy initiation) by Bcl-2, SW063058 enhances autophagic activity without inducing cytotoxicity, apoptosis, or other forms of cell death in vitro.Fórmula:C22H15BrFIN2O2Cor e Forma:SolidPeso molecular:565.17CXCR7 modulator 2
CAS:CXCR7 modulator 2 is a 7-type C-X-C chemokine receptor (CXCR7) modulator with a Ki of 13 nM.Fórmula:C29H42N6O3Cor e Forma:SolidPeso molecular:522.68Z-FY-CHO
CAS:Pyridoxal (Pyridoxaldehyde), a component of vitamin B6, is an aldehyde obtained by oxidizing pyridoxine and is widely found in plants and animals.Fórmula:C26H26N2O5Pureza:95.88%Cor e Forma:SolidPeso molecular:446.5SCH 563705
CAS:SCH 563705 is a CXCR2 and CXCR1 antagonist used in the study of acute respiratory syndrome, chronic obstructive pulmonary disease, and inflammation.Fórmula:C23H27N3O5Pureza:98.03%Cor e Forma:SolidPeso molecular:425.48DCC-3116
CAS:DCC-3116 is an orally active, selective and potent ULK1/2 inhibitor with anticancer activity.DCC-3116 inhibits autophagy and can be used in cancer research.Fórmula:C26H36F3N7O2Pureza:98.55%Cor e Forma:SoildPeso molecular:535.61Gepotidacin mesylate dihydrate
CAS:Gepotidacin mesylate dihydrate (GSK2140944 mesylate dihydrate) is an antibiotic and an inhibitor of bacterial type II topoisomerase.Fórmula:C25H36N6O8SPureza:99.85%Cor e Forma:SolidPeso molecular:580.65VUF11207 trifluoroacetate salt
CAS:VUF11207 trifluoroacetate salt is a useful organic compound for research related to life sciences. The catalog number is T66657 and the CAS number is 1378524-41-4.Fórmula:C29H36F4N2O6Cor e Forma:SolidPeso molecular:584.609Dihydrocelastrol
CAS:Dihydrocelastrol is synthesized by hydrogenation of celastrol, a treterpene isolated from Chinese medicinal plant Tripterygium regelii. Dihydrocelastrol could inhibit cell proliferation and promote apoptosis through caspase-dependent way in vitro. DHCE coFórmula:C29H40O4Cor e Forma:SolidPeso molecular:452.63Pepstatin Ammonium
Pepstatin Ammonium is a specific inhibitor of aspartic proteaseproduced by actinomycetes(hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nMFórmula:C34H66N6O9Pureza:98%Cor e Forma:SolidPeso molecular:702.92Dusquetide
CAS:Dusquetide is a first-in-class innate defense regulator. Dusquetide displays activity in both reducing inflammation and increasing the clearance of bacterial infection.Fórmula:C25H47N9O5Pureza:98%Cor e Forma:SolidPeso molecular:553.709Salvianolic acid B
CAS:<p>Salvianolic acid B (Dan Shen Suan B) is a water-soluble antioxidant from Salvia miltiorrhiza extract with antiplatelet aggregation and antithrombotic effects.</p>Fórmula:C36H30O16Pureza:99.75% - 99.86%Cor e Forma:Yellow SolidPeso molecular:718.61CXCR4-IN-1
CAS:<p>CXCR4-IN-1 (Example C5), with an IC50 of 20 nM, is a potent inhibitor of CXCR4, applicable for the research of various conditions such as cancer, HIV, diabetic</p>Fórmula:C23H32N6Pureza:98%Cor e Forma:SolidPeso molecular:392.54Ref: TM-T79059
Produto descontinuadoEIPA hydrochloride
CAS:EIPA hydrochloride also inhibits Na+/H+-exchanger (NHE) and macropinocytosisEIPA hydrochloride (L593754 hydrochloride) is a TRPP3 channel inhibitor with an IC50 of 10.5 μM.Fórmula:C11H19Cl2N7OPureza:98%Cor e Forma:SolidPeso molecular:336.22FR 167653
CAS:FR 167653 sulfate, an orally active and selective inhibitor of p38 MAPK, is effective in treating inflammation, trauma, and ischemia-reperfusion injury in vivo. It acts as a potent suppressor of TNF-α and IL-1β production through specific inhibition of p38 MAPK activity.Fórmula:C24H20FN5O6SPureza:98%Cor e Forma:SolidPeso molecular:525.51VISTA-IN-2
CAS:<p>VISTA-IN-2 (Compound 1) is a V-domain Ig suppressor of T-cell activation (VISTA) inhibitor that promotes the degradation of VISTA in cells via autophagy,</p>Fórmula:C23H23N3OPureza:98%Cor e Forma:SolidPeso molecular:357.45Ref: TM-T79653
Produto descontinuado
